Medical personnel viewing the visitor of or in discussion



When evaluating penis rigidity according to PHS, the following results were obtained: in the first group, the degree of erectile rigidity was 3.1 before the surgery, by the 7th day after surgery, it reduced by 1.22±0.2. By the 30th and 90th days the result was 2, which corresponds to a sufficiently hard penis, but not hard enough for penetration and sexual intercourse.

The data obtained in the second and third groups did not differ and were characterized by a decrease in penis hardness during the first 7 days, and then by an increasing tendency up to the 3rd degree, which is characterized by a hardness sufficient for penetration.

In the first group, the quality of life according to the QOL scale was 2.1 points before the surgery; 7 days after the surgery it reduced by 2.05±0.3 points, after which a positive increasing tendency was observed; thus, the average life quality level measured 3.7 points on the 30th and 90th days after the surgery.

In the second and third groups, the lowering of the quality of life to 4.15 points was also registered by the 7th day, and by the 30th and 90th day, the quality of life increased to 2.4 points in the second group and to 2.6 points in the third group. No statistically significant differences in the life quality level were observed between the second and third groups.

According to the literature data, no convincing data is currently available on the application of PDE-5 inhibitors for the rehabilitation of sexual function in males after radical prostatectomy for localized prostate cancer. Also, there is no unanimous opinion concerning doses, terms and time of taking PDE-5 inhibitors by this category of patients.

According to the findings by A. Briganti and co-authors [18], in the group where patients constantly took PDE-5 inhibitors, erectile dysfunction was observed much less frequently (37%) compared to the control group (73%, p<0.001), which is generally comparable to the data obtained in the course of the research study. After 3 months, the erectile dysfunction incidence was 75% (15 patients) in the control group, less by 15% (which corresponds to 60%) in the second group (12 patients) and less by 20% in the third group, namely 55% (11 patients).

Some research studies showed evidence of penis shortening by1-3 cm in patients after radical prostatectomy during a one-year observation period. [19, 20] This research study considered changes in penis length during a period of three months after surgical treatment, which demonstrated the length reduction by up to 1.64±0.12 cm in the control group, the penis shortening degree in the second group was lower: 1.175±0.01 cm on the average.

Possible mechanisms responsible for penile length shortening may be cavernosal fibrosis, caused by apoptosis of the smooth muscle cells of cavernous bodies after injury to the pelvic splanchnic nerves (nervi erigentes).

Earlier studies [21] showed that using vacuum extenders allows the penis length to be preserved after radical prostatectomy. At the same time, opinions differ as to using vacuum extenders considering the cavernosal fibrosis hazard resulting from cavernous body ischemia, acidosis and insufficient relaxation of smooth muscles [22]. Our findings show that combining daily intake of PDE-5 inhibitors with daily use of a vacuum extender makes it possible not only to preserve the penis length, but also to increase the penis length by 0.75±0.01 cm.

In modern society, quality of life is an essential part of a patient’s general health and wellness. Numerous research studies dedicated to life quality assessment proved the importance and necessity of developing and introducing patient rehabilitation programs. At present, no distinct and recommended rehabilitation algorithms with proven efficiency are available for patients after radical prostatectomy [7, 14, 15, 16, 17].

Read more



1. Bosetti C., Bertuccio P., Chatenoud L. et al. Trends in mortality from urologic cancars in Europe, 1970-2008. Eur Urol 2011;60:1–15.
2. Analiz uronefrologičeskoj zabolevaemosti v Rossiskoj Federacii po dannym oficialnoj statistiki / Apolihin O.I., Sivkov A.V., Bešliev D.A., Solnzeva T.V., Komarova V.A.// Ėksperimentalnaâ i kliničeskaâ urologiâ. Nr. 2010.
3. Bill-Axelson A, Holmberg L, Filen F, et al; Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008 aug; 100(16):1144–54.
4. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function («trifecta»). Urology 2005 Nov;66(5Suppl):83–94.
5. EAU Guidelines on Prostate Cancer// 2014.
6. Salonia A. et al. Preservation and management of prostatectomy sexual dysfunction Part2: Recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012; 62:273–86.
7. P.V. Glybočko, I.P. Matûhov, Û.G. Alâev, N.D. Ahvlediani, Ž.Š. Inoâtov „Seksual’naâ funkciâ pacientov, perenesših radikal’nujû prostaėktomiû: sovremennyj wzglâd na problemu”, Žurnal urologiâ Nr. 2, S. 112–116, Moskau 2015.
8. Maso E.B., Gamidov S.I., Ovčinnikov R.I., Iremašvili V.V. Novye aspekty patogeneza, profilaktiki i lečeniâ ėrektil’noj disfunkcii u bol’nyh posle radikal’noj prostatėktomii CONSILIUM MEDICUM, 2004 BAND 6 Nr. 7.
9. Puškar D.Û., Bormotin A.V., Govorov A.V. Lečenie ėrektilnoj disfunkcii u pacientov, perenesših radikal’nuû pozadilonnuû porostatėktomiû, s ispol’zovaniem ingibitorov fosfodiesterazy 5 tipa. Kačestvo žizni. Medicina.-2007.-5.- S. 36–41.
10. Roûk R.V. Optimisaciâ metodov diagnostiki i korrekcii osložnenij radikal’noj prostatėktomii na soiskanie učenoj stepeni kandidata medicinskih nauk. RUDN-2007.
11. Sitnikov N.V. Profilaktika osložnenij i rannââ reabilitaciâ bol’nyh posle radikal’noj prostatėktomii dissertaciâ na soiskanie učenoj stepeni doktora medicinskih nauk. FGU 3 CVKG 2008.
12. Veliev E.I., Vanin A.F., Kotov S.V., Šišlo V.K. Sovremennye aspekty patofisiologii i profilaktiki ėrektilnoj disfunkcii i kavernosnogo fibrosa posle radikal’noj prostatėktomii. Urologiâ.-2009.Nr. 2-S.46–51.
13. Kotov S.V. Profilaktika kavernoznogo fibroza polse nervosberegaûŝej radikalnoj prostatėktomii: dissertazija na soiskanie učenoj stepeni kandidata medicinskih nauk. RMAPO 2009. S. 105.
14. Ficarra V, Novara G, Galfano A, Stringari C, Baldassarre R, Cavalleri S et al. Twelve-month selfreported quality of life after retropubic radical prostatectomy: a prospective study with Rand 36-Item Health Survey (Short Form-36). BJU Int 2006; 97: 274.
15. Davison BJ, So AI, Goldenberg SL. Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer. BJU Int. 2007 Oct; 100(4):780-5. Epub 2007 Jun 19.
16. Rakul S.A., S.B. Petrow, M.D. Ivanova, N.N. Petrova Aprobaciâ „Universal’nogo oprosnika kačestva žizni bol’nyh rakom predstatel’noj železy“//Onkourologiâ: ežhekvartal’nyj naučno-praktičeskij žurnal.-2009.-Nr. 2.-S. 64–73.
17. Nâhin V.A. Funkcional’nye rezul’taty i kačestvo žizni pacientov posle radikal’noj pozadilonnoj prostatėktomii dissertaciâ na soiskanie učenoj stepeni kandidata medicinskih nauk. RMAPO 2007. S. 182.
18. Briganti A., Gallina A., Suardi N., Capitanio U., Tutolo M., Bianchi M., Passoni N., Salonia A., Colombo R., Di Girolamo V., Guazzoni G., Rigatti P., Montorsi P. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: A proposal of a novel preoperative risk stratification. J Sex Med 2010; 7:2521–31.
19. McCullogh A. Penile change following radical prostatectomy: Size, smooth muscle atrophy and curve. Curr Urol Rep 2008; 9:492–9.
20. Gontero P., Galzerano M., Bartoletti R., Magnani C., Tizzani A., Frea B., Mondaini N. New insights into the pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function. J Urol 2007; 178:602–7.
21. Kohler TS, Pedro R., Hendlin K., Utz W., Ugarte R., Reddy P., Makhlouf A., Ryndin I., Canales BK., Weiland D., Nakib N., Ramani A., Anderson JK., Monga M.A. Pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 2007; 100:858–62.
22. Sexual Rehabilitation and Cancer Survivorship: A State of Art Review of Current Literature and Management Strategies in Male Sexual Dysfunction Among Prostate Cancer Survivors. J Sex Med 2013; 10 (suppl 1):102–111.
Penimaster Pro Studie
Penimaster Made in Germany
PeniMaster PRO for post-operative treatment of prostate cancer Clinical study 2015/2016
  • After 90 days, the penis rigidity of the non-treated test participants from group 1 was no longer sufficient for the practice of sexual intercourse.
  • In groups 2 and 3 (with PeniMaster PRO), the test participants achieved an erection rigid enough for sexual intercourse.
  • Other studies also show a shortening of the penis after prostate removal by 1-3 cm within one year.
  • The study shows that PeniMaster PRO not only preserves the length of the penis after removal of the prostate, but improves it.
  • Not only recovery from the disease, but also rehabilitation from after-effects is important in modern medicine.
  • There are no standard specifications for treatment after prostatectomy.